News & Updates
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
– With no dose-limiting toxicities observed, treatment of second dose cohort to begin Excerpt from the Press Release: SAN JOSE, Calif., Oct. 13, 2023 /PRNewswire/ — Anixa Biosciences, Inc. (“Anixa” or the “Company”) (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in partnership with Moffitt Cancer Center, it…
Read More
– Key Biomarker Activity Confirmed for Evaluation in Upcoming Phase 1 Study – Excerpt from the Press Release: SAN DIEGO–(BUSINESS WIRE)–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that data from recent preclinical studies of the Company’s Gemini formulation demonstrated its therapeutic potential as a preventative therapy across multiple indications including infection…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 13, 2023 /PRNewswire/ — Inmagene Biopharmaceuticals (“Inmagene”), a clinical stage biotechnology company developing innovative and differentiated therapies for immunological and inflammatory diseases, announced that the first patient has been dosed in a global multicenter Phase 2a study of IMG-007 in adult patients with AA. The study will…
Read More
Preclinical findings support the advancement of BBI-825, a novel, orally available, selective inhibitor of ribonucleotide reductase (RNR), as a differentiated treatment approach for ecDNA-enabled oncogene or resistance gene amplified cancers, including resistance associated with treatment of KRASG12C mutant colorectal cancer (CRC) A second poster presentation reveals insight into the intrinsic genomic plasticity of extrachromosomal DNA…
Read More
– Results showing significant reductions in liver fat content and body weight, no loss of lean muscle mass, and improvement in key markers of metabolism and inflammation published in The Lancet Gastroenterology & Hepatology – – HU6 was well tolerated at once-daily oral doses with adverse events mainly mild or moderate in severity Excerpt from…
Read More
The Ontario Institute for Cancer Research has new funding opportunities: “OICR’s Clinical Translation Pathway (CTP) supports practice-changing research in biomarkers and therapeutics that will advance early detection and intervention research and have a clear path to the clinic and clinical impact. OICR is currently inviting applications for one of the CTP funding streams, Pre-Clinical Acceleration Team…
Read More
PATHFINDER Results Support Feasibility of Multi-Cancer Early Detection (MCED) Testing in Clinical Practice of Eligible Patients Accuracy of Cancer Signal Origin Prediction of MCED Testing Enabled Targeted Diagnostic Evaluations; Majority of Participants Achieved Diagnostic Resolution in Less Than Three Months Adding MCED Testing to Standard of Care Screening More Than Doubled the Number of New…
Read More
Excerpt from the Press Release: SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.…
Read More
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes Excerpt from the Press Release: REDWOOD CITY, Calif., Oct. 05, 2023 (GLOBE NEWSWIRE) — Biomea Fusion, Inc. (“Biomea”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to discovering and developing novel covalent small molecules to…
Read More
Collaboration with OICR and capital from FACIT contributing to a growing hub of medical imaging research in Thunder Bay. Excerpt from the Press Release: When Sasha Bubon arrived in Thunder Bay in January 2010 to begin his master’s studies in physics at Lakehead University, he was starting a whole new chapter personally and scientifically. …
Read MoreRequest Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?